Related Experiment Video
Updated: Aug 21, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Clinical results of proton beam therapy for skull base chordoma
Hiroshi Igaki1, Koichi Tokuuye, Toshiyuki Okumura
1Proton Medical Research Center, University Hospital, University of Tsukuba, Ibaraki, Japan. igaki-tky@umin.ac.jp
Purpose:
To evaluate clinical results of proton beam therapy for patients with skull base chordoma.
Methods And Materials:
Thirteen patients with skull base chordoma who were treated with proton beams with or without X-rays at the University of Tsukuba between 1989 and 2000 were retrospectively reviewed. A median total tumor dose of 72.0 Gy (range, 63.0-95.0 Gy) was delivered. The patients were followed for a median period of 69.3 months (range, 14.6-123.4 months).
Results:
The 5-year local control rate was 46.0%. Cause-specific, overall, and disease-free survival rates at 5 years were 72.2%, 66.7%, and 42.2%, respectively. The local control rate was higher, without statistical significance, for those with preoperative tumors <30 mL. Partial or subtotal tumor removal did not yield better local control rates than for patients who underwent biopsy only as the latest surgery.
Conclusion:
Proton beam therapy is effective for patients with skull base chordoma, especially for those with small tumors. For a patient with a tumor of <30 mL with no prior treatment, biopsy without tumor removal seems to be appropriate before proton beam therapy.
